Gurnet Point Capital

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel tetracycline-based therapies to treat infectious diseases and related public health threats. Its lead programs center on omadacycline, a broad-spectrum tetracycline available in oral and intravenous forms for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, urinary tract infections, and other serious infections, and sarecycline for acne and rosacea. The company emphasizes expertise in advanced tetracycline chemistry to address antibiotic resistance. Paratek collaborates with industry and academic partners, including licenses with Zai Lab and Allergan, a license with Tufts University to develop products for bacterial diseases, and a cooperative R&D agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline. Founded in 1996 and headquartered in Boston, Paratek aims to bring therapies that improve patient outcomes and address public health challenges.

Corium International specializes in the development, manufacture, and commercialization of transdermal and transmucosal drug delivery systems for various therapeutic areas. Its product portfolio includes treatments for hypertension, chronic pain, teeth whitening, osteoporosis, Alzheimer's disease, psychiatric disorders, Parkinson's disease, and motion sickness. The company focuses on enhancing therapeutic profiles and improving patient outcomes through its proprietary technologies.

Naveris is a biotechnology company developing highly sensitive blood tests for cancer detection, monitoring, and recurrence tracking. Its NavDx blood test detects cancer by quantifying tumor-derived DNA fragments in the blood, enabling early diagnosis—including in asymptomatic individuals—real-time monitoring of treatment response, and surveillance for recurrence. The company combines a 3D biomimetic technology that replicates tissue and tumor complexity ex vivo to support oncology research and precision medicine, advancing clinical trial design and matching therapies to patients. Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Alladapt Immunotherapeutics is a privately held biopharmaceutical company focused on developing prescription therapeutics for food allergy. Based in Menlo Park, California, it was founded in 2018. The company’s lead program, ADP101, is a broad-spectrum oral immunotherapy designed to mitigate, treat, and prevent reactions to foods by targeting single or multiple allergen proteins across common allergens.

Fairtility is a company that specializes in developing artificial intelligence-driven solutions to enhance the efficiency of in-vitro fertilization (IVF). Its platform utilizes advanced computer vision algorithms and big data analytics to provide accurate embryo classification and implantation predictions. By offering timely, data-driven assessments of embryo quality, Fairtility aims to improve pregnancy rates while reducing the time and number of IVF cycles required for patients. This innovative approach not only streamlines the IVF process but also supports patients in achieving successful outcomes more effectively.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

Naveris is a biotechnology company developing highly sensitive blood tests for cancer detection, monitoring, and recurrence tracking. Its NavDx blood test detects cancer by quantifying tumor-derived DNA fragments in the blood, enabling early diagnosis—including in asymptomatic individuals—real-time monitoring of treatment response, and surveillance for recurrence. The company combines a 3D biomimetic technology that replicates tissue and tumor complexity ex vivo to support oncology research and precision medicine, advancing clinical trial design and matching therapies to patients. Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts.

Tremeau Pharmaceuticals, Inc. is a clinical-stage company based in Concord, Massachusetts, dedicated to developing and manufacturing non-opioid pain therapies for individuals with rare diseases. Established in 2007, the company specializes in addressing serious rare diseases associated with the cyclooxygenase (COX) or prostanoid pathways, focusing on conditions that present high unmet medical needs. Tremeau's key products include TRM-201, a COX-2 selective nonsteroidal anti-inflammatory drug designed for treating hemophilic arthropathy, and TRM-359. Their innovative therapies aim to improve acute and chronic pain management in specific conditions, offering therapeutic advantages over traditional opioid treatments while ensuring documented efficacy in managing painful inflammatory conditions.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

Alladapt Immunotherapeutics is a privately held biopharmaceutical company focused on developing prescription therapeutics for food allergy. Based in Menlo Park, California, it was founded in 2018. The company’s lead program, ADP101, is a broad-spectrum oral immunotherapy designed to mitigate, treat, and prevent reactions to foods by targeting single or multiple allergen proteins across common allergens.

Corium Innovations is a contract development and manufacturing organization focused on novel drug delivery technologies. The company specializes in providing comprehensive support throughout the entire process, from formulation and product development to commercial-scale manufacturing and packaging. By leveraging its expertise, Corium Innovations assists clients in the development and production of innovative drug delivery solutions, ensuring that they meet the evolving needs of the pharmaceutical industry.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Corium International specializes in the development, manufacture, and commercialization of transdermal and transmucosal drug delivery systems for various therapeutic areas. Its product portfolio includes treatments for hypertension, chronic pain, teeth whitening, osteoporosis, Alzheimer's disease, psychiatric disorders, Parkinson's disease, and motion sickness. The company focuses on enhancing therapeutic profiles and improving patient outcomes through its proprietary technologies.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

Innocoll Holdings plc is a privately held specialty pharmaceutical and medical device company headquartered in Athlone, Ireland. It specializes in the development and manufacture of collagen-based products aimed at addressing surgical needs, particularly in post-operative care. Innocoll's product offerings include CollaGUARD, a bioresorbable collagen film designed to prevent adhesions in various types of surgeries; Collatamp Gentamicin, a surgical implant for infection prevention; Septocoll, a dual-action collagen sponge for infection treatment; and RegenePro, a collagen sponge for dental applications. The company is also advancing innovative product candidates such as XaraColl, an implantable collagen matrix in phase III trials for post-operative pain relief, and Cogenzia, a topical collagen sponge for diabetic foot infections. Innocoll leverages a proprietary technology platform to develop biodegradable products that provide non-opioid alternatives for pain management, enhancing patient care in surgical settings.

BEFORE Brands, Inc. is a science-based consumer products company headquartered in Menlo Park, California, that focuses on providing nutritional products aimed at supporting the health and wellness of families, particularly infants. Founded in 2015, the company utilizes its proprietary Early Adaptive Tolerance blend, which combines whole food proteins and vitamin D, to promote balanced and consistent immune system development in infants. This approach is grounded in research advocating for the inclusion of potentially allergenic foods in early diets to foster immune resilience. The technology behind BEFORE Brands was developed by Dr. Kari Nadeau, a pediatrician and leading researcher in allergy and asthma at Stanford University. The company aims to address the challenges posed by modern living on immune health by offering products designed to support infants before health issues arise.

Crossover Health designs and delivers workplace healthcare services for employers and employees, offering primary care and a broad range of ancillary and advanced services, including urgent and preventive care, chronic disease management, health risk assessment, health education, coaching, biometrics, physical therapy, chiropractic, acupuncture, care coordination, health analytics, and remote care. It operates as a primary care medical group that blends health management services with technology-enabled tools to create a comprehensive employee care experience. Founded in 2010 and based in California, Crossover Health serves client organizations through on-site and partner health centers across Silicon Valley and other U.S. locations, with a focus on improving access to care, enhancing member experience, and reducing healthcare costs for employers and their workforce.

Auregen BioTherapeutics employs advanced 3D bioprinting technology to develop innovative treatments aimed at curing rare disorders, with a focus on congenital craniofacial conditions.

Amazentis SA is a life science company based in Lausanne, Switzerland, founded in 2007. The company specializes in the research and development of bioactive ingredients aimed at advanced therapeutic nutrition, particularly for the aging population. Amazentis focuses on creating products that enhance mitochondrial health, addressing age-related muscle decline by improving mitochondrial activity. Utilizing proprietary technology, the company mimics the effects of certain foods, like pomegranates, to repair damage in mitochondria and promote an active lifestyle. Through its innovative approach, Amazentis aims to meet specific health needs, particularly in hospital settings, by optimizing muscle function and overall well-being.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.